ANRESIS, the Swiss Centre for Antimicrobial Resistance, is a nationwide, representative surveillance system and research platform for antimicrobial resistance and consumption. It is hosted by the Institute for Infectious Diseases (IFIK) of the University of Bern and is financially supported by the Swiss Federal Office of Public Health (FOPH) and the IFIK.
Follow us on LinkedIn
The increasing prevalence of antimicrobial resistance in Campylobacter spp. and Salmonella spp. in Switzerland emphasises the critical need for ongoing surveillance and judicious antibiotic use.
Standardisation proved difficult, but ultimately enabled comparative analysis and benchmarking, as demonstrated on a poster at the SSI Annual Congress in Montreux.
The ANRESIS homepage has been updated and now includes additional data and new functionalities.
Carbapenem resistance in Enterobacterales, Pseudomonas aeruginosa and Acinetobacter spp. increased in hospital respiratory samples from 2007 to 2024, according to an ANRESIS study just published in Eurosurveillance.
The best antibiotic is the antibiotic which is not prescribed. ANRESIS analyzed this special view on the Sentinella data and presented first insights at ESCMID Global 2026.
This article summarises 20 years of ANRESIS—from data collection to the development of interactive tools (in German).
A new study based on ANRESIS data shows an association between antimicrobial consumption and C. difficile incidence in a Swiss medical centre.
What does the AMR situation in India look like – and how is Switzerland connected? A compelling report by SRF’s Trend magazine explores the global dynamics of antimicrobial resistance (in German).
